Hiltonol
- Generic Name
- Hiltonol
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 59789-29-6
- Unique Ingredient Identifier
- 7KYP9TKT70
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT03223103
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT03206047
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT03166254
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03162562
- Locations
- 🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States
🇺🇸VCU Massey Cancer Center, Dalton Oncology Clinic, Richmond, Virginia, United States
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 4
- Registration Number
- NCT03121677
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT03068832
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
- Conditions
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02886065
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
- Conditions
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Gliknik Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02873819
- Locations
- 🇭🇺
Bacs-Kiskun County Teaching Hospital, Kecskemét, Hungary
🇭🇺Medical Center of the University of Pecs, Pecs, Hungary
🇺🇦Ivano-Frankivsk Regional Oncology Center, Ivano-Frankivsk, Ukraine
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Asha Nayak
- Target Recruit Count
- 42
- Registration Number
- NCT02834052
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT02826434
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.